Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Share News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.60
Bid: 1.50
Ask: 1.70
Change: 0.10 (6.67%)
Spread: 0.20 (13.333%)
Open: 1.50
High: 1.625
Low: 1.50
Prev. Close: 1.50
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support Study

Mon, 23rd Nov 2020 19:09

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

ReNeuron Group PLC - Bridgend, Wales-based cell-based therapeutics - Intends to raise gross proceeds up to GBP13.9 million via placing with institutional and other investors alongside up to GBP1.1 million direct subscription. Both will be priced at 70 pence per share with proceeds allowing ReNeuron "to deliver extended clinical data from its ongoing retinitis pigmentosa phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully." Also announces up to GBP2. million open offer.

----------

Lekoil Ltd - African oil exploration and production firm with interests in Nigeria and offshore Namibia - Announces that 15.4% stakeholder Lynchwood Nominees Ltd has requisitioned an extraordinary general meeting where it seeks to oust Chair Mark Simmonds and appoint Michael Ajukwu, Thomas Richardson and George Maxwell to the Lekoil board. Requisition further proposes special resolutions relating to restriction to bee place on the affairs of Lekoil Ltd (Nigeria), Lekoil's principal subsidiary. Leoil in "advanced talks" with new nominated advisor, who will review resolutions proposed. This is expected to extend the due diligence process needed before new nomad is appointed, increasing the risk of share delisting.

----------

Versarien PLC - Cheltenham-based advanced materials engineer - Announces interim results reporting extension and will now release its interim results for the six months ended September 30 by January 31 at the latest. This is in line with Covid-19 guidance allowing for a 1-month extension for reporting interim financial results.

----------

Martin Currie Global Portfolio Trust PLC - investment company focused on long-term returns in excess of the total return from the MSCI All Cos World index - Enters into unsecured three-year GBP30 million term loan facility agreement with Royal Bank of Scotland International Ltd, intended to be fully drawn. Loan will represent approximately 10% of company's net asset value once drawn. Appoints Martin Currie Fund Management Ltd as alternative investment fund manager, having "decided that it is now in the best interests of the company that it has a modest level of structural gearing consistent with the gearing policy".

----------

IQ-AI Ltd - medical software company with headquarters in Jersey - Notes that its Liver Surface Nodularity software application is now CE Mark approved. LSN algorithms process CT images of livers to assess nodules on the surface, conducting a virtual biopsy. This confirms that the LSN meets essential requirements of the European Medical Devices Directive. Follows US Food & Drug Administration's granting of 510(k) market clearance for LSN software earlier in November. IQ-AI says: "These recent regulatory milestones permit IQ-AI's subsidiary, Imaging Biometrics, LLC, the manufacturer of record for LSN, to market and sell the software to the world's two most prominent healthcare markets."

----------

Braemar Shipping Services PLC - London-based provider of technical expertise and professional marine and energy services - Says AqualisBraemar ASA will acquire LOC Group. Baemar Shipping holds an approximately 27% stake in AqualisBraemar, which is an associate company. Combination is intended to create "leading global independent offshore energy and marine consultancy". "Braemar believes this expansion will help generate further momentum for AQB, building on the strong progress stated in its Q3-2020 results, and has therefore shown its support and given the AQB board undertakings to vote in favour of the transaction." Braemar Shipping to hold around 21% stake in enlarged group.

----------

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more
19 Dec 2023 17:00

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.

Read more
5 Dec 2023 11:49

IQ-AI stock rises on positive interim results from glioblastoma trial

(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.

Read more
8 Nov 2023 12:04

IQ-AI says Imaging Biometrics submits paediatric rare disease request

(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.

Read more
18 Oct 2023 17:11

IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.

Read more
9 Oct 2023 12:09

IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.

Read more
8 Sep 2023 10:25

IQ-AI notes vindication of subsidiary's reduced gadolinium approach

(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro.

Read more
18 Aug 2023 12:17

IQ-AI shares jump on subsidiary's GE Healthcare deal

(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc.

Read more
17 Aug 2023 11:21

IQ-AI interim loss narrows amid higher revenue, lower expenses

(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower.

Read more
19 Jul 2023 10:45

IN BRIEF: IQ-AI subsidiary's app adopted by US medical college

IQ-AI Ltd - Jersey-based medical services firm focused on cancer treatment - Says subsidiary Imaging Biometrics LLC's handheld application IB Nimble has been adopted by the Medical College of Wisconsin's Orthopedic Department for use in bone metastases treatment. IB Nimble's designer, Joseph Bovi, is professor of radiation oncology & neurosurgery at MCW. The application was originally designed to help treat brain metastases. IQ-AI says it "provides real-time collaboration amongst multi-disciplinary teams" to "provide optimised treatments faster". Josh McComack, Imaging Biometrics' director of software engineering, says the new installation "demonstrates that IB Nimble is ready for widespread deployment."

Read more
13 Jul 2023 11:36

IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate

IQ-AI Ltd on Thursday - Jersey-based incubator of software and other tools for the treatment of cancer - IQ-AI subsidiary Imaging Biometrics LLC has been granted an orphan drug designation for Gallium Galtolate for the treatment of paediatric glioblastoma multiforme, or GBM, by the US Food & Drug Administration. Says GBM is the most common and aggressive primary brain tumour in adults and children. Imaging Biometrics' application to the FDA was first submitted in April. In June, two pre-clinical studies showed oral GaM inhibits brain tumour growth in children, and the results were consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin.

Read more
27 Jun 2023 11:47

IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth

IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.